BMO Capital analyst Kelly Bania maintains Walmart (NYSE:WMT) with a Outperform and lowers the price target from $165 to $160.
Bristol Myers Squibb’s Abecma Becomes First CAR T Approved For Use In Earlier Lines Of Therapy For Patients With Relapsed Or Refractory Multiple Myeloma In Japan
Bristol Myers Squibb's Abecma® Becomes First CAR T Approved for Use in Earlier Lines of Therapy for Patients with Relapsed or Refractory Multiple Myeloma in JapanTOKYO, December 6, 2023 - Bristol-Myers Squibb
